[go: up one dir, main page]

MX9302917A - Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene. - Google Patents

Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.

Info

Publication number
MX9302917A
MX9302917A MX9302917A MX9302917A MX9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A
Authority
MX
Mexico
Prior art keywords
derivatives
famaceutical
procedure
preparation
formulation containing
Prior art date
Application number
MX9302917A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9302917A publication Critical patent/MX9302917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen derivados de proteína C humana con alta actividad y dependencia reducida sobre la activación de la trombina. Estos derivados difieren de las formas nativas o naturales de la proteína C humana en sus velocidades incrementadas de activación, sus actividades funcionales y sus estructuras de carbohidratos. También se describen los compuestos de DNA, los vectores de transferencia, los vectores de expresión y los transformadores útiles para la producción de estos derivados.
MX9302917A 1992-05-21 1993-05-19 Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene. MX9302917A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (1)

Publication Number Publication Date
MX9302917A true MX9302917A (es) 1993-11-01

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302917A MX9302917A (es) 1992-05-21 1993-05-19 Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.

Country Status (23)

Country Link
US (1) US5453373A (es)
EP (1) EP0575054B1 (es)
JP (1) JP3564150B2 (es)
KR (1) KR100291529B1 (es)
CN (1) CN1080658A (es)
AT (1) ATE286121T1 (es)
AU (1) AU661901B2 (es)
BR (1) BR9301944A (es)
CA (1) CA2096604C (es)
CZ (1) CZ286016B6 (es)
DE (1) DE69333727T2 (es)
DK (1) DK0575054T3 (es)
ES (1) ES2233925T3 (es)
FI (1) FI932282A (es)
HU (1) HU218408B (es)
IL (1) IL105757A0 (es)
MX (1) MX9302917A (es)
MY (1) MY110664A (es)
NO (1) NO311299B1 (es)
NZ (1) NZ247651A (es)
PH (1) PH29911A (es)
PT (1) PT575054E (es)
RU (1) RU2122004C1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2288143C (en) 1997-04-28 2012-08-21 Eli Lilly And Company Activated protein c formulations
TR199903020T2 (xx) * 1997-06-05 2000-08-21 Eli Lilly And Company Trombotik bozukluklar�n tedavisi i�in y�ntemler.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
JP2003506006A (ja) * 1998-07-31 2003-02-18 イーライ・リリー・アンド・カンパニー 活性化プロテインｃの寒冷顆粒化
JP2002527490A (ja) 1998-10-22 2002-08-27 イーライ・リリー・アンド・カンパニー 敗血症を治療する方法
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
IL142220A0 (en) 1998-11-20 2002-03-10 Lilly Co Eli Method of treating viral hemorrhagic fever
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
EP1237917A2 (en) * 1999-11-19 2002-09-11 Eli Lilly And Company Protein c derivatives
CA2399267A1 (en) * 2000-02-02 2001-08-09 Eli Lilly And Company Protein c derivatives
JP2003521938A (ja) * 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL154999A0 (en) * 2000-10-18 2003-10-31 Maxygen Aps Protein c or activated protein c-like molecules
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EP2178556B1 (en) * 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
CN106488773B (zh) 2014-04-16 2020-02-11 Zz生物技术有限责任公司 Apc类似物用于创伤愈合的用途
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C

Also Published As

Publication number Publication date
CA2096604A1 (en) 1993-11-22
PT575054E (pt) 2005-03-31
DE69333727T2 (de) 2005-12-15
EP0575054A2 (en) 1993-12-22
JP3564150B2 (ja) 2004-09-08
CA2096604C (en) 2003-12-16
KR100291529B1 (ko) 2001-06-01
CZ94893A3 (en) 1994-01-19
AU661901B2 (en) 1995-08-10
US5453373A (en) 1995-09-26
ES2233925T3 (es) 2005-06-16
AU3869993A (en) 1993-11-25
EP0575054A3 (en) 1995-04-19
DE69333727D1 (de) 2005-02-03
NO931840D0 (no) 1993-05-19
MY110664A (en) 1999-01-30
EP0575054B1 (en) 2004-12-29
HU9301461D0 (en) 1993-09-28
NO931840L (no) 1993-11-22
NO311299B1 (no) 2001-11-12
HU218408B (hu) 2000-08-28
KR930023370A (ko) 1993-12-18
IL105757A0 (en) 1993-09-22
BR9301944A (pt) 1993-11-30
ATE286121T1 (de) 2005-01-15
PH29911A (en) 1996-09-16
CN1080658A (zh) 1994-01-12
NZ247651A (en) 1995-03-28
FI932282A (fi) 1993-11-22
RU2122004C1 (ru) 1998-11-20
CZ286016B6 (cs) 1999-12-15
DK0575054T3 (da) 2005-04-25
FI932282A0 (fi) 1993-05-19
HUT69615A (en) 1995-09-28
JPH0680698A (ja) 1994-03-22

Similar Documents

Publication Publication Date Title
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
ATE162221T1 (de) Herstellung von glukoseoxidase in rekombinanten systemen
MY102472A (en) Preparation of funtional human urokinase proteins.
DK172089D0 (da) 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf
PT83872A (de) Arzneimittel
FI864124A (fi) Heterocykliska foereningar och deras framstaellning samt anvaendning.
ES2035384T3 (es) Procedimiento para la esterilizacion de sangre, plasma, derivados de la sangre y del plasma, suspensiones celulares o similares.
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
PT86771A (pt) Process for preparing 4-substituted benzamide derivatives with anticonvulsant activity
NO902104D0 (no) Kosmetisk blanding.
DK90188D0 (da) Kombinationsprodukter indeholdende picolin- eller 2-pyridyloxyeddikesyre-derivater, praeparater omfattende saadanne produkter og anvendelse deraf som herbicider
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
ES2051953T3 (es) Derivados isomeros de trimetilbiciclo(4,3,0)nonano.
ATE209500T1 (de) Ein neuartiges, antineoplastisches cytokin
AU1786988A (en) Isoxazoles with nootropic activity
NO902405D0 (no) Vevplasminogenaktivatorderivat, dna-sekvens og ekspresjonsplasmid, samt fremgangsmaate for fremstilling av plasmidet.
DK381989D0 (da) Maerkede benzodiazepiner
DE3773322D1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.
SE8503513D0 (sv) Farmaceutiska och kosmetiska kompositioner, vilka som verksam bestandsdel innehaller acetyl-10-triacetoxi-1,8,9-antracen
ATE104966T1 (de) 9-(acylamino)tetrahydroacridinderivate und wahrnehmungssteigernde mittel davon als aktiver wirkstoff.
ES1004605Y (es) Nuevo dispositivo de union de las ramas de peinetas y pasadores articulados para el cabello.